Europe says Ariad's Iclusig can stay

Share this article:

Europe's doors remain open for Ariad Pharma's leukemia drug Iclusig. PMLive reported Monday that the European Medicines Agency says the drug can stay on the market, but the EMA is restricting the eligible patient population.

Ariad has said since halting US marketing and distribution that it expects the overall fallout will be that the FDA requires a more restricted label, meaning a smaller patient group. The FDA asked the company to stop drug-related operations over concerns that it could be associated with blood clots.

The company has retrenched since cutting its US push in October by both laying off 40% of its staff and pursuing a streamlining effort that will cut costs by 35% and power the company through the middle of 2015.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.